There is no single success rate for stem-cell therapy — it depends on the condition, cell type and what counts as success. Here is what the published evidence reports, condition by condition, with trial stage and approval status.
Direct answer: “Stem-cell therapy” has no single success rate. Results cannot be transferred between different products, indications, study designs or endpoints. Use each condition page to inspect the current registry snapshot, then read the underlying studies rather than a promotional percentage.
A registry listing does not establish efficacy. Check study design, status, endpoints, results, product identity and regulatory status before drawing conclusions.
There is no single success rate. Outcomes depend on the condition, the cell type, the study design and how “success” is defined (symptom relief, biomarker change, or cure). Most regenerative therapies are still investigational, so reported figures come from early-phase trials and clinic series rather than large randomised trials. The strongest evidence is in haematopoietic transplantation for blood and immune disorders; for most other conditions, benefit means slowed progression or symptom improvement in a subset of patients, not a cure.
Because “stem cell therapy” covers many cell types and dozens of conditions at very different evidence levels. A figure quoted for knee osteoarthritis says nothing about multiple sclerosis. Honest reporting is condition-by-condition, with the trial stage and what was actually measured — which is how we present it on each condition page.
Haematopoietic stem-cell transplantation is established for selected blood and immune disorders. For other uses, check the current product-specific authorisation and trial stage. The former EU authorisation for darvadstrocel in complex perianal Crohn’s fistulae was withdrawn in December 2024.
StemCellAtlas is a source-first research and cost-planning guide. It separates registry and regulator evidence from heterogeneous commercial observations.
Get an honest assessment